Advertisement covers CROI 2014

CROI 2014: The Latest on HIV Antiretroviral Therapy (Video)

April 1, 2014

Daniel R. Kuritzkes, M.D., and Philip Grant, M.D., sit down to talk about the latest developments in antiretroviral treatment. They discuss the prospects of long-acting therapies, which could help treat people having trouble with adherence. They also chat about the trend toward simpler, better-tolerated regimens, and how to best individualize treatment for patients.

Watch the video to learn more:

More on the panelists:

  • Daniel R. Kuritzkes, M.D., Chief of the Division of Infectious Disease, at Brigham and Women's Hospital
  • Philip Grant, M.D., Assistant Professor at Stanford University

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Warren Tong is the research editor for and

Follow Warren on Twitter: @WarrenAtTheBody.

Copyright © 2014 Remedy Health Media, LLC. All rights reserved.

This article was provided by It is a part of the publication The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014).


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.